The DOI matches its Crossref record; 75 of the 76 references it cites were found in a registry or an index.
Passive Immunization with Tau Oligomer Monoclonal Antibody Reverses Tauopathy Phenotypes without Affecting Hyperphosphorylated Neurofibrillary Tangles
Open accessAbstract
Recent findings suggest that tau oligomers, which form before neurofibrillary tangles (NFTs), are the true neurotoxic tau entities in neurodegenerative tauopathies, including Alzheimer's disease (AD). Studies in animal models of tauopathy suggest that tau oligomers play a key role in eliciting behavioral and cognitive impairments. Here, we used a novel tau oligomer-specific monoclonal antibody (TOMA) for passive immunization in mice expressing mutant human tau. A single dose of TOMA administered either intravenously or intracerebroventricularly was sufficient to reverse both locomotor and memory deficits in a mouse model of tauopathy for 60 d, coincident with rapid reduction of tau oligomers but not phosphorylated NFTs or monomeric tau. Our data demonstrate that antibody protection is mediated by extracellular and rapid peripheral clearance. These findings provide the first direct evidence in support of a critical role for tau oligomers in disease progression and validate tau oligomers as a target for the treatment of AD and other neurodegenerative tauopathies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“we observed elevated levels of TauO in the brain, cerebrospinal fluid (CSF), and sera from AD patients with clinical severity, 9 , 15 , 16 , 17 , 18 , 19 , 20”
From Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies (2024) · cites this paper as [16]
In the citing paper
“significant advancements have been made in the development of novel anti‐tau antibodies that specifically recognize disease‐relevant tau strains and conformations.”
From Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies (2024) · cites this paper as [16]
In the citing paper
“These antibodies target unique conformational epitopes, independent of specific linear amino acid sequences, and exhibit preferences for different subsets of tau oligomers.”
From Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies (2024) · cites this paper as [16]
In the citing paper
“In addition, monoclonal antibodies against the amino-terminal or repeat domain (306–320) region209–215, oligomeric tau216,217, misfolded tau201,218,219, pSer202220,221, pThr231208 pSer409222, pSer413223 and pSer422224 have proved to be efficacious in tauopathy models.”
From Tau-targeting therapies for Alzheimer disease (2018) · cites this paper as [216]
In the citing paper
“Indeed, several reports are available of antibodies that are capable of reducing tau levels and preventing spreading without apparently entering neurons216,218,239.”
From Tau-targeting therapies for Alzheimer disease (2018) · cites this paper as [216]
Citations
Cites
1 retracted
Masliah, E., Rockenstein, E. M., Mante, M., Crews, L. A., Spencer, B. J., Adame, A., Patrick, C., Trejo, M., Ubhi, K. K., Rohn, T. T., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019338 · Cited by 422 · cited 5×
“…exclusive and it has been demonstrated that different clearance mechanisms can be activated to different degrees depending on the antibody and its target (DeMattos et al., 2001; Levites et al., 2006; Sigurdsson, 2008; Golde et al., 2009; Masliah et al., 2011; Morgan, 2011; Ubhi and Masliah, 2011).”
BackgroundInfluentialRetractedSynapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.-M., Iwata, N., Saido, T. C., Maeda, J., Suhara, T., Trojanowski, J. Q., & Lee, V. M.-Y. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.010 · Cited by 2,208 · cited 1×
“…metastable tau aggregates such as NFTs are not causally linked to tauopathy phenotypes in animal models (Wittmann et al., 2001; Santacruz et al., 2005; Berger et al., 2007; Yoshiyama et al., 2007; Polydoro et al., 2009; LasagnaReeves et al., 2011b; Spires-Jones et al., 2011; Cowan et al., 2012).”
BackgroundTau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174 · cited 3×
“In addition, tau mutations can cause disorders such as familial frontotemporal dementia (for review, see Ballatore et al., 2007).”
BackgroundInfluentialTau Suppression in a Neurodegenerative Mouse Model Improves Memory Function
SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., et al. (2005) · Science · doi:10.1126/science.1113694 · Cited by 2,014
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease
Gómez‐Isla, T., Hollister, R., West, H., Mui, S., Growdon, J. H., Petersen, R. C., Parisi, J. E., & Hyman, B. T. (1997) · Annals of Neurology · doi:10.1002/ana.410410106 · Cited by 1,489 · cited 1×
“…human AD brain, NFT-containing neurons can survive for decades (Morsch et al., 1999) and neuronal loss precedes or is independent of NFT formation (Gómez-Isla et al., 1997; Terry, 2000; Maeda et al., 2006; van de Nes et al., 2008), suggesting that other tau species may contribute to earlier…”
BackgroundLewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van Slegtenhorst, M., Gwinn-Hardy, K., Murphy, M. P., Baker, M., Yu, X., et al. (2000) · Nature Genetics · doi:10.1038/78078 · Cited by 1,371 · cited 3×
“The JNPL3 mouse model (Lewis et al., 2000) expresses a frontotemporal dementia-associated human mutant tau transgene (P301L) and has been used previously for tau immunotherapy (Asuni et al., 2007; Chai et al., 2011; Bi et al., 2011).”
MethodDeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298
Augustinack, J. C., Schneider, A., Mandelkow, E.-M., & Hyman, B. T. (2002) · Acta Neuropathologica · doi:10.1007/s004010100423 · Cited by 998
Flagged first, then by citations
1 of the 76 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–278 of 278
Krestová, M., Říčný, J., & Bartoš, A. (2018) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2018.05.004 · Cited by 12
Chiasseu, M., Fesharaki‐Zadeh, A., Saito, T., Saido, T. C., & Strittmatter, S. M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105059 · Cited by 11
Alhadidy, M. M., Stemmer, P. M., & Kanaan, N. M. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.108263 · Cited by 13
“To detect pathological tau conformations using conformation-dependent antibodies ( i . e ., TOC1, TOMA1, TNT2, and Alz50), tau samples must be kept under native conditions (38, 48, 58, 64, 122).”
Esteves-Villanueva, J. O., Trzeciakiewicz, H., Loeffler, D. A., & Martić, S. (2014) · Biochemistry · doi:10.1021/bi501272x · Cited by 12
Validation of Tau Antibodies for Use in Western Blotting and ImmunohistochemistryPreprint
Ellis, M. J., Lekka, C., Tulmin, H., O'Brien, D. P., Dhayal, S., Zeissler, M., Knudsen, J. G., Kessler, B. M., Morgan, N. G., Todd, J. A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.13.536711 · Cited by 15
Tang, J., Sun, R., Wan, J., Xu, Z., Gong, Y., Zou, Y. F., & Zhang, Q. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00103 · Cited by 10
Alhadidy, M. M., & Kanaan, N. M. (2024) · Biochemical Society Transactions · doi:10.1042/bst20230596 · Cited by 10
Fukumoto, H., Kao, T., Tai, C., Jang, M., & Miyamoto, M. (2024) · The FASEB Journal · doi:10.1096/fj.202401704r · Cited by 9
“29,58 (3) Rabbit polyclonal antibody of T22 (IgG) has been identified to have affinities to LMWoTau species such as dimer/trimmers (110/195 kD) using one-site direct ELISA and SEC.”
Tang, J., Xu, Z., Wang, F., Guan, L., Qi, B., & Zou, Y. F. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c02353 · Cited by 9
Opportunities for Conformation-Selective Antibodies in Amyloid-Related Diseases
Westwood, M., & Lawson, A. D. G. (2015) · Antibodies · doi:10.3390/antib4030170 · Cited by 9
“JNPL3 mouse model resulted in a reduced tau oligomer level and improved motor test performance [85].”
Verelst, J., Geukens, N., Eddarkaoui, S., Vliegen, D., Smidt, E. D., Rosseels, J., Franssens, V., Molenberghs, S., François, C., Stoops, E., et al. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00048 · Cited by 11
Vitale, F., Ortolan, J., Volpe, B. T., Marambaud, P., Giliberto, L., & d’Abramo, C. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01003-7 · Cited by 9
Focusing on oligomeric tau as a therapeutic target in Alzheimer’s disease and other tauopathies
Rayman, J. B. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2206561 · Cited by 11
“For example, injection of oligomeric tauspecific antibody clears oligomeric tau from the hippocampus and other key brain regions, and is accompanied by rescue of motor and/or cognitive phenotypes associated with transgene expression [79,80,105,106].”
BackgroundPetry, F. R., Nicholls, S. B., Hébert, S. S., & Planel, E. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6598-4_15 · Cited by 10
Yu, Z.-Y., Li, W.-W., Yang, H.-M., Mañucat-Tan, N. B., Wang, J., Wang, Y.-R., Sun, B.-L., Hu, Z.-C., Zhang, L.-L., Tan, L., et al. (2020) · Neurotoxicity Research · doi:10.1007/s12640-020-00161-9 · Cited by 9
“The latter is the main component of neurofibrillary tangles (NFTs) (Avila et al. 2016; Castillo-Carranza et al. 2014), which may spread throughout the cortex by interneural tau transfer and is reported to accelerate the pathogenesis of AD (Nobuhara et al.”
BackgroundMcArthur, N., Squire, J. D., Onyeachonam, O. J., Bhatt, N. N., Jerez, C., Holberton, A. L., Tessier, P. M., Wood, L. B., Kayed, R., & Kane, R. S. (2024) · Biomaterials Science · doi:10.1039/d4bm00707g · Cited by 8
Self-citationTau-based therapies for Alzheimer’s disease: Promising novel neuroprotective approaches
Sayas, C. L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814037-6.00005-7 · Cited by 9
Gyparaki, M. T., Arab, A., Sorokina, E. M., Santiago-Ruiz, A. N., Bohrer, C. H., Xiao, J., & Lakadamyali, M. (2021) · Biophysical Journal · doi:10.1016/j.bpj.2020.11.442 · Cited by 8
Tauopathy induces degeneration and impairs regeneration of sensory nerves in the cornea
Li, S., Shi, S., Luo, B., Xia, F., Ha, Y., Merkley, K. H., Motamedi, M., Zhang, W., & Liu, H. (2021) · Experimental Eye Research · doi:10.1016/j.exer.2021.108900 · Cited by 10
Martín‐Ávila, A., Modak, S., Rajamohamedsait, H. B., Dodge, A., Shamir, D. B., Krishnaswamy, S., Sandusky‐Beltran, L. A., Walker, M., Lin, Y., Congdon, E. E., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116291 · Cited by 7
Sengupta, U., & Kayed, R. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3629-9_9 · Cited by 8
Self-citationAnatabine Attenuates Tau Phosphorylation and Oligomerization in P301S Tau Transgenic Mice
Paris, D. (2014) · Brain Disorders & Therapy · doi:10.4172/2168-975x.1000126 · Cited by 6
“While anatabine reduces tau phosphorylation and tau oligomers in detergent soluble and insoluble fractions of brain homogenates, further work will be required to determine whether anatabine can also prevent the formation of neurofibrillary tangle although it is apparent that tau oligomers rather than neurofibrillary t…”
BackgroundDale Schenk One Year Anniversary: Fighting to Preserve the Memories
Overk, C., & Masliah, E. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-171071 · Cited by 5
Mautone, L., Cordella, F., Soloperto, A., Ghirga, S., Gennaro, G. D., Gigante, Y., & Angelantonio, S. D. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01920-x · Cited by 9
The current state of amyloidosis therapeutics and the potential role of fluorine in their treatment
Dabur, M., Loureiro, J. A., & Pereira, M. D. C. (2022) · Biochimie · doi:10.1016/j.biochi.2022.08.003 · Cited by 6
Recent Advancements in the Early Diagnosis and Treatment of Alzheimer's Disease
Wu, Y., Fu, L., Li, Q., Gao, X., Zhang, Y., Jin, C., Ding, F., Hong, S. C., Cai, H., & Li, Y. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202300181 · Cited by 4
Soeda, Y., Hayashi, E., Nakatani, N., Ishigaki, S., Takaichi, Y., Tachibana, T., Riku, Y., CHAMBERS, J. K., Koike, R., Mohammad, M., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-65949-7 · Cited by 5
“However, no epitopes have been reported for either antibody 39,40 .”
BackgroundJiang, L., Roberts, R., Wong, M., Zhang, L., Webber, C. J., Kilci, A., Jenkins, M., Sun, G., Rashad, S., Sun, J., et al. (2023) · Research Square · doi:10.1101/2023.03.28.534515 · Cited by 5
“Studies suggest that MAPT oligomers are the more toxic species that induce neurodegeneration [25, 26, 34-36].”
BackgroundMethodiPSC screening identifies CACNA2D2 as a potential therapeutic target for FTLD-Tau.
Imamura, K., Nagahashi, A., Okusa, A., Sakasai, T., Tsukita, K., Kutoku, Y., Ohsawa, Y., Sunada, Y., Sahara, N., Kanaan, N., et al. (2025) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2025.151484 · Cited by 4
Development of an Effective Alzheimer’s Vaccine
Marciani, D. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809819-6.00011-3 · Cited by 4
Passive Immunotherapy in Alzheimer’s Disease
Dolan, P. J., & Zago, W. M. (2018) · InTech eBooks · doi:10.5772/intechopen.76299 · Cited by 4
Saleem, T., Möbius, W., Schmitz, M., Correia, A. D. S., Thomas, C., Canaslan, S., Hermann, P., Goebel, S., Zafar, S., Root, E., et al. (2026) · Acta Neuropathologica · doi:10.1007/s00401-026-02998-4 · Cited by 4
Tang, J., Wang, F., Xu, Z., Zou, Y. F., & Zhang, Q. (2025) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.4c07977 · Cited by 3
Sigurdsson, E. M. (2016) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-3560-4_8 · Cited by 3
Zhai, Z., Kong, F., Zhu, Z., Dai, J., Cai, J., Xie, D., Shen, Y., Xu, Y., & Sun, T. (2023) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2023.11.011 · Cited by 4
Martínez, P., Jury, N., Patel, H., You, Y., Perkins, A., You, Y., Lee‐Gosselin, A., Vidal, R., & Lasagna‐Reeves, C. A. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251372603 · Cited by 3
Self-citationYeast surface display of full‐length human microtubule‐associated protein tau
Wang, S., & Cho, Y. K. (2019) · Biotechnology Progress · doi:10.1002/btpr.2920 · Cited by 3
“, 2012) and TOMA-1 (Castillo-Carranza et al., 2014).”
Neurodegenerative Diseases as Protein Folding Disorders
Baker, J. D., Webster, J. M., Shelton, L. B., Koren, J., Uversky, V. N., Blair, L. J., & Dickey, C. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811304-2.00009-2 · Cited by 3
Central and peripheral tau retention modulated by an anti-tau antibodyPreprint
Solorzano, A. G., Brady, M., Bhatt, N. N., Johnson, A., Burgess, B., Leyva, H., Puangmalai, N., Jerez, C., Wood, R. W., Kayed, R., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.17.553682 · Cited by 4
Self-citationWasielewska, J. M., Bajracharya, R., Johnston, R. L., Chaves, J. C. S., Pébay, A., Oikari, L. E., Götz, J., Nisbet, R. M., & White, A. R. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.24.563706 · Cited by 2
Reevaluating tau reduction as a therapeutic approach for tauopathies: Insights and perspectives
Sun, X., Ogbolu, V. C., Baas, P. W., & Qiang, L. (2023) · Cytoskeleton · doi:10.1002/cm.21790 · Cited by 2
“The targeted immunotherapy, which focuses specifically on oligomeric tau rather than NFTs, demonstrated remarkable potential for behavioral recovery and prolonged disease progression in tauopathy mouse models (Bittar et al., 2022; Castillo-Carranza et al., 2014).”
BackgroundHaque, M. A., Montalbano, M., Khan, S., Puangmalai, N., Bhatt, N. N., Shchankin, N., Jerez, C., & Kayed, R. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167995 · Cited by 2
“We hypothesize that the toxic tau conformation-specific antibodies, TOMA-1 and TTCM-1 could clear toxic TauO from extracellular space or prevent them from seeding further [31].”
InfluentialSelf-citationRNA-based therapeutics for Alzheimer’s disease and related tauopathies: challenges and opportunities
Rajbanshi, B., Brentari, I., Denti, M. A., Cummings, J. L., & Guruacharya, A. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100585 · Cited by 2
“Most current therapeutic strategies focus on targeting abnormal tau protein through immunotherapies [5,6], small molecules [7], or inhibitors of tau-related post-translational modifications [8,9].”
The glymphatic system and its role in the development of Alzheimer’s disease
Vorobʼev, S. V., & Yanishevskij, S. N. (2021) · Translational Medicine · doi:10.18705/2311-4495-2021-8-3-14-21 · Cited by 2
TAU IMMUNOTHERAPY FOR ALZHEIMER’S (Review Article)
Chandrakumaran, A., Achuthaprasad, A., DANIEL, P., & JACOB, J. (2022) · EXPERIMENTAL & CLINICAL MEDICINE GEORGIA · doi:10.52340/jecm.2022.02.15 · Cited by 2
Lifestyles of a Toxic Twosome: A Novel Tau Strain Induced by α-Synuclein Oligomers
Jackson, G. R. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.08.003 · Cited by 2
Self-citationArrant, A. E., & Roberson, E. D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801942-9.00006-9 · Cited by 3
Chatterjee, P., Cho, M. K., Bui, H. T., & Ham, S. (2021) · Bulletin of the Korean Chemical Society · doi:10.1002/bkcs.12334 · Cited by 2
Stephens, G. S., You, J. C., Fu, C.-H., & Chin, J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809324-5.21126-7 · Cited by 1
Mucci, N. J. (2015) · KU ScholarWorks (The University of Kansas)
Functional implications of tau-fyn interactions in Alzheimer's disease
Lau, H. W. D. (2015)
News from the Society for Neuroscience Annual Meeting
Talan, J. (2015) · Neurology Today · doi:10.1097/01.nt.0000475925.08618.0e
Active and Passive Immunotherapy Against Tau: Effects and Potential Mechanisms
Yanamandra, K., Diamond, M. I., & Holtzman, D. M. (2016) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-3560-4_9
Tau-Directed Immunotherapy for Alzheimer's Disease
Schroeder, S. K. (2017) · Digital Commons - University of South Florida (University of South Florida)
Immunotherapy for the Treatment of Alzheimer’s Disease
Farooqui, A. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809937-7.00009-4
Phillips, E. C. (2017) · Research Portal (King's College London)
Development and characterization of cell models of tau aggregation
Cavallini, A. (2018) · UCL Discovery (University College London)
Potential Neuroprotective Strategies for Concussion and Chronic Traumatic Encephalopathy
Farooqui, A. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813596-9.00009-2
The Analysis of Exosomal Tau Release and its Regulation
Bradshaw, A. (2018) · UCL Discovery (University College London)
Modulation of neuronal function by tau, alpha synuclein or carbon dioxide
Hill, E. (2026) · Warwick Research Archive Portal (University of Warwick) · doi:10.82444/warw.33830401
Kullmann, F. A. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735993693.793561876
Wongsodirdjo, P., Caruso, A. C., Yong, A., Lester, M. A., Vella, L. J., Hung, Y. H., & Nisbet, R. M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.15.563554
Analysis of Immunotherapy Methods for Alzheimer's Disease
Huang, J. (2025) · Theoretical and Natural Science · doi:10.54254/2753-8818/2025.au23579
Saleem, T., Möbius, W., Schmitz, M., Correia, A. D. S., Thomas, C., Canaslan, S., Hermann, P., Goebel, S., Zafar, S., Root, E., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.10.693456
Xia, F., Ha, Y., Shi, S., Li, Y., li, S., Luisi, J. D., Kayed, R., Motamedi, M., Liu, H., & Zhang, W. (2021) · Figshare · doi:10.6084/m9.figshare.14302635
Self-citationGibbons, G. S., Kim, S.-J., Wu, Q., Riddle, D. M., Leight, S. N., Changolkar, L. N., Xu, H., Meymand, E. S., O’Reilly, M., Zhang, B., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13192098
Gibbons, G. S., Kim, S.-J., Wu, Q., Riddle, D. M., Leight, S. N., Changolkar, L. N., Xu, H., Meymand, E. S., O’Reilly, M., Zhang, B., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13192104
Gibbons, G. S., Kim, S.-J., Wu, Q., Riddle, D. M., Leight, S. N., Changolkar, L. N., Xu, H., Meymand, E. S., O’Reilly, M., Zhang, B., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13192095
Gibbons, G. S., Kim, S.-J., Wu, Q., Riddle, D. M., Leight, S. N., Changolkar, L. N., Xu, H., Meymand, E. S., O’Reilly, M., Zhang, B., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13192101
Vautheny, A. (2019) · theses.fr (ABES) · doi:10.70675/1812d71aze8d9z48d6z87d1z5a23a4e81953
Altered neuronal activity in the hippocampal CA3 region in an in vitro model of tauopathy
Goncalves, A. (2020) · theses.fr (ABES) · doi:10.70675/b42db6dez88a0z4a14z93eez8f51d19d46f5
Seplovich, G., Muthusamy, S., Anderson, A., Waithe, O. Y., Kobeissy, F. H., Wang, K., & Tharakan, B. (2026) · Microcirculation · doi:10.1111/micc.70059
Tau physiology and pathology: impacts on cellular structures and neurodegenerative diseases
Akbari, V., & Bahramikia, S. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02328-w
“…clear pathological tau have shown promise in preclinical studies and are currently being evaluated in clinical trials for AD and other tauopa-thies (Castillo-Carranza et al. 2014 ; Collin et al. 2014 ; Dai et al. 2015; Pedersen and Sigurdsson 2015; Yanamandra et al. 2013; Siebrand et al. 2025; De…”
Neurotoxic Tau Oligomers: Isolation, Preparation, and Characterization
Khan, S., Haque, M. A., & Kayed, R. (2026) · Neuromethods · doi:10.1007/978-1-0716-5234-3_9
Self-citationBöken, D., Beltran-Lobo, P., Wu, Y., Rowe, L. A., Fertan, E., Croft, C. L., Jiménez-Sánchez, M., Cox, D., & Klenerman, D. (2026) · Advanced Science · doi:10.1002/advs.77822 · Cited by 1
“…with different physico-chemical properties of tau, we performed immunoprecipitations using five tau-targeting antibodies: HT7 (pan tau), TOMA1 [ 15 ] (oligomeric tau), MC1 [ 16 ] (fibrillar tau), and two phospho-tau antibodies, AT8 [ 17 ] (an established pathological tau marker recognizing…”
Mercado, C., Amaro, A., Martínez-Pinto, J., Vidal, R., Jury, N., & Lasagna‐Reeves, C. A. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-026-04065-x
Self-citation
Metadata
- Authors
- Castillo-Carranza, D. L., Sengupta, U., Guerrero-Muñoz, M. J., Lasagna-Reeves, C. A., Gerson, J. E., Singh, G., Estes, D. M., Barrett, A. D. T., Dineley, K. T., Jackson, G. R., & Kayed, R.
- Affiliations
- The University of Texas Medical Branch at Galveston (US)
- ORCID
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2014-03-19
- Volume
- 34
- Issue
- 12
- Pages
- 4260-4272
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- PMC
- PMC6608097
- OpenAlex
- W1990986671
- Cited by
- 278
- References
- 76
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 15 · 2023: 21 · 2022: 13 · 2021: 20 · 2020: 30 · 2019: 25 · 2018: 34 · 2017: 27 · 2016: 21 · 2015: 28 · 2014: 23
- FWCI
- 21.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alzheimer's Drug Discovery Foundation
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- tau oligomers, passive immunization, monoclonal antibodies, TOMAS, tauopathy, Alzheimer's disease, neurofibrillary tangles, hyperphosphorylated tau, locomotor deficits, memory impairment, antibody clearance, neurodegenerative disease treatment
- MeSH terms
- Alzheimer Disease, Animals, Disease Models, Animal, Immunization, Passive, Phosphorylation, Neurofibrillary Tangles, tau Proteins, Disease Progression, Tauopathies, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
